HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M800516-MCP200v1 8/4/791    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Glossary Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kuzmanov, U. Articles by Diamandis, E. P. Search for Related Content PubMed PubMed Citation Articles by Kuzmanov, U. Articles by Diamandis, E. P. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 8:791-798, 2009.
© 2009 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Research

Differential N-glycosylation of Kallikrein 6 Derived from Ovarian Cancer Cells or the Central Nervous System^*

Uros Kuzmanov^,, Nianxin Jiang^,, Christopher R. Smith^¶, Antoninus Soosaipillai and Eleftherios P. Diamandis^,,¶,||

From the Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto M5G 1X5, Ontario, Canada, Departemnt of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada, and ^¶ Department of Clinical Biochemistry, University Health Network, Toronto, Ontario M5G 1X5, Canada

Ovarian cancer causes more deaths than any other gynecological disorder. Perturbed glycosylation is one of the hallmarks of this malignancy. Kallikrein 6 (KLK6) elevation in serum is a diagnostic and prognostic indicator in ovarian cancer. The majority of ovarian carcinomas express high levels of KLK6, which diffuses into the circulation. Under physiological conditions, KLK6 is expressed highly in the central nervous system and found at high levels in cerebrospinal fluid from where it enters the circulation. Our aim was to characterize and compare the N-glycosylation status of this protein in ovarian cancer ascites fluid and cerebrospinal fluid. Anion-exchange chromatography was used to reveal different post-translational modifications on the two isoforms. Mobility gel shift Western blot analysis coupled with glycosidase digestion showed that the molecular weight difference between the two isoforms was because of differential glycosylation patterns. The presence of a single N-glycosylation site on KLK6 was confirmed by site-directed mutagenesis. Using a Sambucus nigra agglutinin-monoclonal antibody sandwich enzyme-linked immunosorbent assay approach, it was shown that ovarian cancer-derived KLK6 was modified with 2-6-linked sialic acid. The structure and composition of glycans of both KLK6 isoforms was elucidated by glycopeptide monitoring with electrospray ionization-Orbitrap tandem mass spectrometry. Therefore, the extensive and almost exclusive sialylation of KLK6 from ovarian cancer cells could lead to the development of an improved biomarker for the early diagnosis of ovarian carcinoma.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. M. Drake, W. Cho, B. Li, A. Prakobphol, E. Johansen, N. L. Anderson, F. E. Regnier, B. W. Gibson, and S. J. Fisher Sweetening the Pot: Adding Glycosylation to the Biomarker Discovery Equation Clin. Chem., February 1, 2010; 56(2): 223 - 236. [Abstract] [Full Text] [PDF]

				Z. Darula and K. F. Medzihradszky Affinity Enrichment and Characterization of Mucin Core-1 Type Glycopeptides from Bovine Serum Mol. Cell. Proteomics, November 1, 2009; 8(11): 2515 - 2526. [Abstract] [Full Text] [PDF]